Related Experiment Video
Updated: Jan 22, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Phenformin as an Anticancer Agent: Challenges and Prospects
Mª Eugenia García Rubiño1, Esmeralda Carrillo2,3,4,5,6, Gloria Ruiz Alcalá2,4
1Department of Physical Chemistry, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain.
Abstract:
Currently, there is increasing evidence linking diabetes mellitus (especially type 2 diabetes mellitus) with carcinogenesis through various biological processes, such as fat-induced chronic inflammation, hyperglycemia, hyperinsulinemia, and angiogenesis. Chemotherapeutic agents are used in the treatment of cancer, but in most cases, patients develop resistance. Phenformin, an oral biguanide drug used to treat type 2 diabetes mellitus, was removed from the market due to a high risk of fatal lactic acidosis. However, it has been shown that phenformin is, with other biguanides, an authentic tumor disruptor, not only by the production of hypoglycemia due to caloric restriction through AMP-activated protein kinase with energy detection (AMPK) but also as a blocker of the mTOR regulatory complex. Moreover, the addition of phenformin eliminates resistance to antiangiogenic tyrosine kinase inhibitors (TKI), which prevent the uncontrolled metabolism of glucose in tumor cells. In this review, we evidence the great potential of phenformin as an anticancer agent. We thoroughly review its mechanism of action and clinical trial assays, specially focusing on current challenges and future perspectives of this promising drug.
Insights
Phenformin, a diabetes drug, shows promise as an anticancer agent by disrupting tumors and overcoming resistance to cancer therapies. Further research explores its potential in clinical trials.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus is linked to increased cancer risk via inflammation, hyperglycemia, and hyperinsulinemia.
- Cancer treatment resistance to chemotherapy and antiangiogenic tyrosine kinase inhibitors (TKI) is a significant clinical challenge.
- Phenformin, a biguanide antidiabetic drug, was withdrawn due to lactic acidosis risk but exhibits anticancer properties.
Purpose of the Study:
- To review the anticancer potential of phenformin.
- To elucidate phenformin's mechanisms of action in cancer.
- To discuss clinical trials, challenges, and future perspectives of phenformin as an anticancer agent.
Main Methods:
- Review of existing literature on phenformin, diabetes, and cancer.
- Analysis of phenformin's biological pathways, including AMPK and mTOR.
- Examination of clinical trial data and resistance mechanisms.
Main Results:
- Phenformin acts as a tumor disruptor by inducing hypoglycemia and blocking the mTOR complex.
- It enhances the efficacy of antiangiogenic tyrosine kinase inhibitors (TKI) by eliminating resistance.
- Phenformin's anticancer effects are linked to energy metabolism regulation via AMPK.
Conclusions:
- Phenformin demonstrates significant potential as an anticancer agent.
- Its ability to overcome drug resistance and disrupt tumor growth warrants further clinical investigation.
- Despite past safety concerns, phenformin's therapeutic benefits in oncology merit continued research and development.
More Related Videos
Related Concept Videos
Subviral Agents
Air-entraining Agents
Masking and Demasking Agents
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
Oral Hypoglycemic Agents: Glinides
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Chemical Agents for Microbial Control

